JPH11508358A - 間葉性骨格前駆細胞についてのマーカーとしてのfgfr3 - Google Patents
間葉性骨格前駆細胞についてのマーカーとしてのfgfr3Info
- Publication number
- JPH11508358A JPH11508358A JP9502869A JP50286997A JPH11508358A JP H11508358 A JPH11508358 A JP H11508358A JP 9502869 A JP9502869 A JP 9502869A JP 50286997 A JP50286997 A JP 50286997A JP H11508358 A JPH11508358 A JP H11508358A
- Authority
- JP
- Japan
- Prior art keywords
- fgfr3
- cells
- cartilage
- progenitor cells
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.間葉性骨格前駆細胞を同定するための方法であって、 (a)リガンド−レセプター結合を可能にする条件下で、線維芽細胞増殖因子レ セプター3(FGFR3)結合因子を、アッセイされた細胞または組織に適用する工程 ;および (b)どの細胞が該FGFR3結合因子に結合しているかを決定する工程を包含し、該 細胞は間葉性骨格前駆細胞である、 方法。 2.前記FGFR3結合因子が、FGFR3に対して特異的な抗体である、請求項1に記載 の方法。 3.前記FGFR3結合因子が、線維芽細胞増殖因子レセプター9(FGF9)である、請 求項1に記載の方法。 4.間葉性骨格前駆細胞の実質的に純粋な培養物を得るための方法であって: (a)FGFR3結合因子を、間葉性骨格前駆細胞を含む細胞供給源に適用する工程; および (b)FGFR3結合因子が結合する細胞を該供給源から分離する工程を包含し、該細 胞は間葉性骨格前駆細胞の実質的に純粋な培養物を提供する、 方法。 5.前記細胞供給源が、内生的であり、増殖していない軟骨細胞、脱分化した線 維芽細胞様の細胞、軟骨膜、滑膜、骨膜から得られる細胞であるか、または該細 胞供給源が胚性である、請求項4に記載の方法。 6.表面にFGFR3を特徴として有する骨格前駆細胞の実質的に純粋な培養物。 7.軟骨膜および/または滑膜および骨膜に接する領域由来の骨格前駆細胞の実 質的に純粋な培養物。 8.前軟骨幹細胞の実質的に純粋な培養物。 9.請求項4に記載の方法により得られる、請求項6に記載の骨格前駆細胞。 10.軟骨細胞の生存能を維持するに適した培地、および請求項6から8のいず れかに記載の実質的に純粋な培養物を含む、骨および軟骨の修復のための薬学的 組成物。 11.FGFR3に結合するFGFファミリーのメンバーをさらに含有する、請求項10 に記載の薬学的組成物。 12.FGF9を含有する、請求項11に記載の薬学的組成物。 13.増殖を許容する接着性の環境、および請求項6から8のいずれかに記載の 実質的に純粋な培養物を含有する、骨または軟骨移植に適した移植物。 14.FGFR3に結合するFGFファミリーのメンバーをさらに含有する、請求項13 に記載の移植物。 15.FGF9を含有する、請求項14に記載の移植物。 16.軟骨および骨の成長が貧弱であると予測される、他の発育不全および骨端 軟骨の損傷を罹患した軟骨形成不全の患者を処置する方法であって: 請求項11または12に記載の薬学的組成物、または請求項14または15に 記載の移植物を、それぞれ所望の成長部位または修復部位に、投与または移植す る工程を包含する、方法。 17.前記投与された細胞が内生的である、請求項16に記載の方法。 18.前記細胞が同種異系である、請求項16に記載の方法。 19.組織またはサンプル内の軟骨−骨腫瘍を検出する方法であって、 (i)アッセイされた組織またはサンプルをFGFR3結合因子と接触させる工程; (ii)該FGFR3結合因子が結合する細胞の存在を検出する工程を包含し、陽性の 検出が、該アッセイされた組織またはサンプル内の軟骨−骨腫瘍の存在を示す、 方法。 20.前記軟骨−骨腫瘍が、外骨症および骨増殖体からなる群より選択される、 良性腫瘍である、請求項19に記載の方法。 21.薬学的に受容可能なキャリアおよび活性成分としての細胞傷害性部分に結 合したFGFR3結合因子を含む、軟骨−骨腫瘍の処置のための薬学的組成物。 22.前記FGFR3結合因子がFGF9である、請求項21に記載の薬学的組成物。 23.前記FGFR3結合因子がFGFR3に対する抗体である、請求項21に記載の薬学 的組成物。 24.軟骨−骨腫瘍細胞を特異的に破壊するための方法であって、治療有効量の 細胞傷害性部分に結合したFGFR3結合因子を、そのような処置を必要とする被験 体に投与する工程を包含する、方法。 25.前記FGFR3結合因子がFGF9である、請求項24に記載の方法。 26.前記FGFR3結合因子がFGFR3に対する抗体である、請求項24に記載の方法 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13795P | 1995-06-12 | 1995-06-12 | |
US60/000,137 | 1995-06-12 | ||
PCT/IL1996/000010 WO1996041620A1 (en) | 1995-06-12 | 1996-06-12 | Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004192332A Division JP2004305221A (ja) | 1995-06-12 | 2004-06-29 | 間葉性骨格前駆細胞についてのマーカーとしてのfgfr3 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11508358A true JPH11508358A (ja) | 1999-07-21 |
JP3673281B2 JP3673281B2 (ja) | 2005-07-20 |
Family
ID=21690089
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9502870A Ceased JPH11507828A (ja) | 1995-06-12 | 1996-06-12 | Fgfr3に対して特異的なリガンドとしてのfgf9 |
JP50286997A Expired - Lifetime JP3673281B2 (ja) | 1995-06-12 | 1996-06-12 | 間葉性骨格前駆細胞についてのマーカーとしてのfgfr3 |
JP2004192332A Withdrawn JP2004305221A (ja) | 1995-06-12 | 2004-06-29 | 間葉性骨格前駆細胞についてのマーカーとしてのfgfr3 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9502870A Ceased JPH11507828A (ja) | 1995-06-12 | 1996-06-12 | Fgfr3に対して特異的なリガンドとしてのfgf9 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004192332A Withdrawn JP2004305221A (ja) | 1995-06-12 | 2004-06-29 | 間葉性骨格前駆細胞についてのマーカーとしてのfgfr3 |
Country Status (12)
Country | Link |
---|---|
US (2) | US6447783B1 (ja) |
EP (3) | EP0836380B1 (ja) |
JP (3) | JPH11507828A (ja) |
CN (1) | CN1195982A (ja) |
AT (2) | ATE213590T1 (ja) |
AU (2) | AU715996B2 (ja) |
CA (2) | CA2224229A1 (ja) |
DE (2) | DE69619526T2 (ja) |
DK (2) | DK0833620T3 (ja) |
ES (2) | ES2173289T3 (ja) |
IL (2) | IL122473A (ja) |
WO (2) | WO1996041620A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008091013A1 (ja) * | 2007-01-23 | 2008-07-31 | Yokohama City University | 軟骨細胞調製方法 |
JP2016506914A (ja) * | 2013-01-16 | 2016-03-07 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
JP2020015733A (ja) * | 2019-08-19 | 2020-01-30 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
US11021528B2 (en) | 2016-07-07 | 2021-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale | Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8083745B2 (en) | 2001-05-25 | 2011-12-27 | Conformis, Inc. | Surgical tools for arthroplasty |
US8234097B2 (en) | 2001-05-25 | 2012-07-31 | Conformis, Inc. | Automated systems for manufacturing patient-specific orthopedic implants and instrumentation |
US8480754B2 (en) | 2001-05-25 | 2013-07-09 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US8735773B2 (en) | 2007-02-14 | 2014-05-27 | Conformis, Inc. | Implant device and method for manufacture |
US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US7534263B2 (en) | 2001-05-25 | 2009-05-19 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US7468075B2 (en) | 2001-05-25 | 2008-12-23 | Conformis, Inc. | Methods and compositions for articular repair |
US7799077B2 (en) | 2002-10-07 | 2010-09-21 | Conformis, Inc. | Minimally invasive joint implant with 3-dimensional geometry matching the articular surfaces |
US7618451B2 (en) | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US8771365B2 (en) | 2009-02-25 | 2014-07-08 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs, and related tools |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8556983B2 (en) | 2001-05-25 | 2013-10-15 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
US6136040A (en) * | 1998-03-05 | 2000-10-24 | Washington University | Animal model with disrupted FGF-9 gene |
US7184814B2 (en) | 1998-09-14 | 2007-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
US7239908B1 (en) | 1998-09-14 | 2007-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
AU772012B2 (en) | 1998-09-14 | 2004-04-08 | Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US20020058036A1 (en) * | 1999-07-27 | 2002-05-16 | Michael Jeffers | Novel fibroblast growth factor and nucleic acids encoding same |
WO2001024833A2 (en) | 1999-10-06 | 2001-04-12 | Tigenix N.V. | In vivo assay for testing the phenotypic stability |
US7482114B2 (en) | 1999-10-06 | 2009-01-27 | Tigenix N.V. | In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation |
CA2386506C (en) | 1999-10-06 | 2012-02-21 | Tigenix N.V. | Isolation of precursor cells and their use for tissue repair |
AU2001239765A1 (en) * | 2000-02-14 | 2001-08-27 | Smith Kline Beecham Corporation | Novel compounds |
WO2001068854A2 (en) * | 2000-03-13 | 2001-09-20 | Amgen, Inc. | Fibroblast growth factor-like molecules and uses thereof |
WO2002022014A1 (en) | 2000-09-14 | 2002-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
EP1364066A2 (en) * | 2001-02-02 | 2003-11-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying functional nucleic acids |
CA2447694A1 (en) | 2001-05-25 | 2002-12-05 | Imaging Therapeutics, Inc. | Methods and compositions for articular resurfacing |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US8439926B2 (en) | 2001-05-25 | 2013-05-14 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
WO2002102972A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
WO2003076467A1 (en) * | 2002-03-14 | 2003-09-18 | Yeda Research And Development Co. Ltd. | Compositions and methods for inducing and regulating bone formation |
WO2004022095A1 (en) * | 2002-09-04 | 2004-03-18 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
AU2003290757A1 (en) | 2002-11-07 | 2004-06-03 | Conformis, Inc. | Methods for determing meniscal size and shape and for devising treatment |
AU2011211453B2 (en) * | 2004-06-21 | 2015-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
CA2571243A1 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US20080260694A1 (en) * | 2004-09-24 | 2008-10-23 | Angioblast Systems, Inc. | Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof |
US7391676B2 (en) * | 2004-12-22 | 2008-06-24 | Asml Netherlands B.V. | Ultrasonic distance sensors |
US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
US20070049739A1 (en) * | 2005-08-30 | 2007-03-01 | Biomet Manufacturing Corp. | Method and system for extracting blood-derived growth factors |
TWI584796B (zh) | 2006-02-06 | 2017-06-01 | 康福美斯公司 | 患者可選擇式關節置換術裝置及外科工具 |
US8623026B2 (en) | 2006-02-06 | 2014-01-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
EP2591756A1 (en) | 2007-02-14 | 2013-05-15 | Conformis, Inc. | Implant device and method for manufacture |
WO2009111626A2 (en) | 2008-03-05 | 2009-09-11 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
AU2009246474B2 (en) | 2008-05-12 | 2015-04-16 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8808303B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US8808297B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
EP2679600A1 (en) | 2009-03-25 | 2014-01-01 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
BRPI1014917A2 (pt) | 2009-04-16 | 2016-04-19 | Conformis Inc | "dispositivos de artroplastia de junta específica para páciente para reparo de ligamento" |
US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
CA2782137A1 (en) | 2009-12-11 | 2011-06-16 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
WO2012112694A2 (en) | 2011-02-15 | 2012-08-23 | Conformis, Inc. | Medeling, analyzing and using anatomical data for patient-adapted implants. designs, tools and surgical procedures |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
KR20150124941A (ko) | 2013-03-10 | 2015-11-06 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | 골 계통 질환 치료약 및 그 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5270197A (en) * | 1990-12-20 | 1993-12-14 | The Children's Medical Center Corporation | Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor |
JP3385040B2 (ja) * | 1991-02-14 | 2003-03-10 | 武田薬品工業株式会社 | グリア活性化因子およびその製造法 |
EP0608546A3 (en) * | 1992-12-22 | 1995-09-27 | Takeda Chemical Industries Ltd | Glia activating factor (gaf), antibodies against it and their uses. |
AU6446194A (en) * | 1993-03-17 | 1994-10-11 | Whittier Institute For Diabetes And Endocrinology, The | Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
-
1996
- 1996-06-12 JP JP9502870A patent/JPH11507828A/ja not_active Ceased
- 1996-06-12 DE DE69619526T patent/DE69619526T2/de not_active Expired - Lifetime
- 1996-06-12 JP JP50286997A patent/JP3673281B2/ja not_active Expired - Lifetime
- 1996-06-12 AT AT96917641T patent/ATE213590T1/de not_active IP Right Cessation
- 1996-06-12 IL IL12247396A patent/IL122473A/xx not_active IP Right Cessation
- 1996-06-12 EP EP96917641A patent/EP0836380B1/en not_active Expired - Lifetime
- 1996-06-12 ES ES96917641T patent/ES2173289T3/es not_active Expired - Lifetime
- 1996-06-12 AU AU60144/96A patent/AU715996B2/en not_active Ceased
- 1996-06-12 WO PCT/IL1996/000010 patent/WO1996041620A1/en active IP Right Grant
- 1996-06-12 AU AU60145/96A patent/AU721773B2/en not_active Ceased
- 1996-06-12 EP EP02022340A patent/EP1342476A3/en not_active Withdrawn
- 1996-06-12 DE DE69624239T patent/DE69624239T2/de not_active Expired - Fee Related
- 1996-06-12 US US08/981,030 patent/US6447783B1/en not_active Expired - Lifetime
- 1996-06-12 IL IL12247296A patent/IL122472A/xx not_active IP Right Cessation
- 1996-06-12 AT AT96917640T patent/ATE225652T1/de not_active IP Right Cessation
- 1996-06-12 WO PCT/IL1996/000011 patent/WO1996041523A1/en active IP Right Grant
- 1996-06-12 DK DK96917640T patent/DK0833620T3/da active
- 1996-06-12 DK DK96917641T patent/DK0836380T3/da active
- 1996-06-12 CA CA002224229A patent/CA2224229A1/en not_active Abandoned
- 1996-06-12 CA CA2223701A patent/CA2223701C/en not_active Expired - Lifetime
- 1996-06-12 EP EP96917640A patent/EP0833620B1/en not_active Expired - Lifetime
- 1996-06-12 ES ES96917640T patent/ES2183957T3/es not_active Expired - Lifetime
- 1996-06-12 CN CN96194719A patent/CN1195982A/zh active Pending
-
2002
- 2002-08-02 US US10/212,357 patent/US20020193309A1/en not_active Abandoned
-
2004
- 2004-06-29 JP JP2004192332A patent/JP2004305221A/ja not_active Withdrawn
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008091013A1 (ja) * | 2007-01-23 | 2008-07-31 | Yokohama City University | 軟骨細胞調製方法 |
JPWO2008091013A1 (ja) * | 2007-01-23 | 2010-05-20 | 公立大学法人横浜市立大学 | 軟骨細胞調製方法 |
US9951312B2 (en) | 2007-01-23 | 2018-04-24 | Yokohama City University | Method for preparation of cartilage cell |
JP2016506914A (ja) * | 2013-01-16 | 2016-03-07 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
US11702642B2 (en) | 2013-01-16 | 2023-07-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
US11814654B2 (en) | 2013-01-16 | 2023-11-14 | Institut National De La Sante Et De La Recherche Medicale | Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
US11021528B2 (en) | 2016-07-07 | 2021-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale | Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof |
US11697678B2 (en) | 2016-07-07 | 2023-07-11 | Pfizer Inc. | Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof |
JP2020015733A (ja) * | 2019-08-19 | 2020-01-30 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3673281B2 (ja) | 間葉性骨格前駆細胞についてのマーカーとしてのfgfr3 | |
US6517872B1 (en) | FGFR3 as a marker for mesenchymal skeletal progenitor cells | |
US9862753B2 (en) | FGF-2 variants having N-terminal deletions and increased receptor selectivity and methods of use thereof | |
JP4235689B2 (ja) | 骨疾患を処置するための骨形成タンパク質 | |
EP0575555B1 (en) | Protein-induced morphogenesis | |
Jelic et al. | Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep | |
EP3553077B1 (en) | Peptide for repairing cartilage and treating osteoarthritis | |
CA2104678C (en) | Protein-induced morphogenesis | |
Shimazu et al. | Syndecan-3 and the control of chondrocyte proliferation during endochondral ossification | |
CA2222609A1 (en) | Methods and uses of connective tissue growth factor as an induction agent | |
JPH04505607A (ja) | 骨誘導タンパク | |
JPH08503198A (ja) | Op−3誘導形態形成 | |
US9089598B2 (en) | Method of treating connective tissue defect using chondrocytes selected for phenotypic stability | |
WO1993018147A1 (en) | Protein compound capable of inhibiting tumoral growth | |
JPH08501558A (ja) | モルフォゲン誘発性肝再生 | |
JP2001514026A (ja) | 骨形態形成蛋白を発現する遺伝子操作された細胞 | |
US20030206912A1 (en) | FGFR3 as a marker for mesenchymal skeletal progenitor cells | |
KR19990082999A (ko) | 연골 유도를 위한 골유도 단백질과 배화 인자의 조합물의 용도 | |
Sires | The isolation and characterization of a chondrogenic inductive agent (CIA) from soluble rat incisor dentin matrix proteins | |
Lauder et al. | P51. Isolation and extractability of fibromodulin | |
AU3766593A (en) | Protein compound capable of inhibiting tumoral growth | |
Heyligers et al. | Use of Recombinant Human OP-1 in Cartilage Repair–in Vitro and in Vivo Studies | |
EP1220873A1 (en) | Novel protein component and encoding nucleic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040824 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050422 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090428 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100428 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110428 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120428 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130428 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |